What the gut tells researchers about COVID To view this email as a web page,
click here Gilead, Merck step in to help India's drug manufacturers fight surging COVID-19 outbreak UHS posts $209M profit in Q1 after treating high number of COVID-19 patients Insights into how COVID outsmarts the gut's immune response could point to new treatments COVID-19 tracker: J&J shot could prevent 1,400 deaths in 6 months, CDC says; Pfizer's oral drug could come by year end Jubilant wraps up early clinical tests of oral remdesivir, plots further studies UPDATED Coronavirus tracker: CDC eases outdoor mask guidelines for fully vaccinated people Kry raises $316M to scale its telehealth platform across Europe Centene has added 320K members on ACA exchanges under special enrollment period Featured Story | By Noah Higgins-Dunn Gilead Sciences and Merck have unveiled plans to boost production for their antiviral COVID-19 drugs in India to help the nation battle its worsening outbreak. read more |
| |
|---|
|
Top Stories By Robert King Universal Health Services posted a $209 million profit for the first quarter of 2021 as a double-digit increase in patient service revenue offset lingering declines in volumes. read more By Arlene Weintraub European researchers used 3D tissue models, or organoids, of the human gut to determine that a particular subpopulation of cells is most affected by SARS-CoV-2. The enhanced understanding of those cells mount an immune response to the virus could enhance the search for new COVID-19 therapies, they said. read more By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky Johnson & Johnson's COVID-19 vaccine could save up to 1,400 lives in the next six months if the U.S. continues to administer the vaccine, a new CDC reports shows. Pfizer chief Albert Bourla tells CNBC that the company's oral antiviral could be available by the end of the year. And more headlines. read more By Nick Paul Taylor Jubilant Pharma has completed initial tests of its oral remdesivir formulation in healthy volunteers. The progress led Jubilant to seek authorization to run additional studies of its oral twist on Gilead’s intravenous COVID-19 antiviral. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Andrea Park With more than $300 million in additional backing, Kry will pursue a strategy of rapid expansion. The startup plans to recruit new members to its team, look into potential acquisitions and partnerships and grow its platform in nearly every direction. read more By Paige Minemyer Centene Corporation posted $699 million in profit for the first quarter of 2021, up from $46 million in the prior-year quarter. read more |
|
